Concepedia

68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours

Rohini Sharma, Wai Meng Wang, Siraj Yusuf, Joanne Evans, Ramya Ramaswami, Florian Wernig, Andrea Frilling, Francesco Mauri, Adil Al‐Nahhas, Eric O. Aboagye,

Radiotherapy and Oncology · 2019 · 106 citations · 23 references

DOI

Concepts

References

23

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

, , +17

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

, , +17

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

Michael Gabriel, Clemens Decristoforo, Dorota Kendler et al. · Journal of Nuclear Medicine · 2007 · 1K citations · Full text

, , +17

Hepatic neuroendocrine metastases: does intervention alter outcomes?1

Ronald S. Chamberlain, David Canes, Karen T. Brown et al. · Journal of the American College of Surgeons · 2000 · 619 citations

, , +14